Alterity Therapeutics (ATHE) has released an update.
Alterity Therapeutics is set to present new data from the bioMUSE Natural History Study in a webcast, with insights on its lead drug ATH434’s Phase 2 trial endpoints for treating neurodegenerative diseases. The discussion will feature CEO Dr. David Stamler and key opinion leader Dr. Daniel Claassen, highlighting the study’s implications for Multiple System Atrophy treatment. The company continues to focus on innovative treatments for Parkinsonian disorders, leveraging its broad drug discovery platform.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.
